undamentalytics Newsletter

Clearpoint Neuro, Inc. income statement

In fiscal 2025, Clearpoint Neuro, Inc. reported revenue of $37.0m, up 17.8% on the year before, operating income of −$24.2m (a -65.4% margin) and net income of −$25.5m, or −$0.90 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Clearpoint Neuro, Inc.: income statement, annual
Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue3454456771113162124313745
Cost of revenue———————32445710121418
Gross profit———————4579111414192328
Research and development6423323323591112121416
Selling, general and administrative5567884444581012121620
Operating income−10−6−3−7−5−9−7−6−5−5−6−13−16−22−20−24−32
Interest expense2230111111110—125
Net interest income————————————−001——
Income before tax——————————————−19−25−36
Income tax——000—————000000−0
Net income−9−8−6−7−5−8−8−7−6−6−7−14−16−22−19−26−36
Diluted EPS−$56.00−$0.52−$0.15−$0.12−$0.08−$4.48−$2.93−$0.93−$0.56−$0.42−$0.43−$0.69−$0.68−$0.90−$0.70−$0.90−$1.21
Diluted shares (average)——1m1m1m2m3m8m11m13m16m21m24m25m27m28m30m
EBITDA−9−6−3−7−5−9−7−6−5−4−6−13−16−22−19−23−32

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CLPT vs KRMDCLPT vs TLSICLPT vs SNWVCLPT vs SENS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Clearpoint Neuro, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Clearpoint Neuro, Inc.